Combined risk effects of IDE and NEP gene variants on Alzheimer disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 80, Issue 11, 2009, Pages 1268-1270

  Vepsalainen S ^a   Helisalmi, S ^a   Mannermaa, A ^b   Pirttila T ^a   Soininen, H ^a   Hiltunen, M ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INSULYSIN; MALE; MIDDLE AGED; NEPRILYSIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 72249091682     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.160002     Document Type: Article

References (13)

1. Iwata N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain Abeta by neprilysin. Science 2001;292:1550-1552 (Pubitemid 32493424)
2. Qiu WQ, Walsh DM, Ye Z, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998;273:32730-32738 (Pubitemid 28557658)
3. Yasojima K, McGeer EG, McGeer PL. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res 2001;919:115-121 (Pubitemid 33016594)
4. Cook DG, Leverenz JB, McMillan PJ, et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 2003;162:313-319
5. Helisalmi S, Hiltunen M, Vepsalainen S, et al. Polymorphisms in neprilysin gene affect the risk of Alzheimer's disease in Finnish patients. J Neurol Neurosurg Psychiatry 2004;75:1746-1748 (Pubitemid 39611478)
6. Vepsalainen S, Parkinson M, Helisalmi S, et al. Insulin-degrading enzyme is genetically associated with Alzheimer's disease in the Finnish population. J Med Genet 2007;44:606-608 (Pubitemid 47441771)
7. Lehtovirta M, Soininen H, Helisalmi S, et al. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism. Neurology 1996;46:413-419 (Pubitemid 26081323)
8. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944 (Pubitemid 14076461)
9. Tsukamoto K, Watanabe T, Matsushima T, et al. Determination by PCR-RFLP of apo E genotype in a Japanese population. J Lab Clin Med 1993;121:598-602. (Pubitemid 23112654)
10. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-2229 (Pubitemid 34680308)
11. Tapiola T, Pirttila T, Mehta PD, et al. Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease. Neurobiol Aging 2000;21:735-740 (Pubitemid 30759085)
12. Farris W, Schutz SG, Cirrito JR, et al. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol 2007;18:18. (Pubitemid 47339241)
13. Kim M, Hersh LB, Leissring MA, et al. Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. J Biol Chem 2007;282:7825-7832 (Pubitemid 47093556)